Inventor · disambiguated record
Michael Bruno Plewe
Also filed as: PLEWE MICHAEL · PLEWE MICHAEL B · PLEWE MICHAEL BRUNO
16 granted patents·21 pending applications·311 citations·filing 1998–2025
93Inventor score
Top patents by PatentIndex Score
37 records- 0195US6875760B2Glucagon antagonists/inverse agonistsNOVO NORDISK AS·Filed 2002·Granted Apr 5, 2005·56 cites·80 claims
- 0295US6503949B1Glucagon antagonists/inverse agonistsNORO NORDISK AS·Filed 2000·Granted Jan 7, 2003·67 cites·56 claims
- 0391US7696213B24-methylpyridopyrimidinone compoundsPFIZER·Filed 2007·Granted Apr 13, 2010·21 cites·16 claims
- 0488US8633204B24-methylpyridopyrimidinone compoundsCHENG HENGMIAO·Filed 2012·Granted Jan 21, 2014·11 cites·4 claims
- 0587US7138408B2HIV integrase inhibitors, pharmaceutical compositions and methods for their useAGOURON PHARMA·Filed 2005·Granted Nov 21, 2006·13 cites·2 claims
- 0687US6613942B1Glucagon antagonists/inverse agonistsNOVO NORDISK AS·Filed 1998·Granted Sep 2, 2003·96 cites·50 claims
- 0786US8273755B24-methylpyridopyrimidinone compoundsCHENG HENGMIAO·Filed 2010·Granted Sep 25, 2012·10 cites·15 claims
- 0886US7468375B2Inhibitors of the HIV integrase enzymePFIZER·Filed 2005·Granted Dec 23, 2008·12 cites·20 claims
- 0984US7368571B2HIV-Integrase inhibitors, pharmaceutical compositions and methods for their usePFIZER·Filed 2006·Granted May 6, 2008·4 cites·2 claims
- 1079US7001912B2HIV-integrase inhibitors, pharmaceutical compositions, and methods for their useAGOURON PHARMA·Filed 2004·Granted Feb 21, 2006·12 cites·14 claims
- 1178US2025388587A1Tropomyosin receptor kinase (trk) degradation compounds and methods of useCULLGEN SHANGHAI INC·Filed 2025·Application pending·0 cites
- 1277US7135482B2HIV-integrase inhibitors, pharmaceutical compositions, and methods for their useAGOURON PHARMA·Filed 2003·Granted Nov 14, 2006·7 cites·7 claims
- 1376US11352328B2Heterocyclic compounds for the treatment of arenavirusARISAN THERAPEUTICS INC·Filed 2017·Granted Jun 7, 2022·2 cites·29 claims
- 1476US2024400570A1Tropomyosin receptor kinase (trk) degradation compounds and methods of useCULLGEN SHANGHAI INC·Filed 2024·Application pending·0 cites
- 1569US2024066136A1Modified proteins and protein degradersCULLGEN SHANGHAI INC·Filed 2023·Application pending·0 cites
- 1664US2025325678A1Cyclic-amp response element binding protein (cbp) and/or adenoviral e1a binding protein of 300 kda (p300) degradation compounds and methods of useCULLGEN SHANGHAI INC·Filed 2025·Application pending·0 cites
- 1764US2022281825A1Heterocyclic compounds for the treatment of arenavirus infectionARISAN THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1863US2008221154A1Hiv-integrase inhibitors, pharmaceutical compositions, and methods for their usePFIZER·Filed 2008·Application pending·0 cites
- 1962US2023057177A1Modified proteins and protein degradersCULLGEN SHANGHAI INC·Filed 2021·Application pending·0 cites
- 2060US2009143592A1Glucagon Antagonists/Inverse AgonistsNOVO NORDISK AS·Filed 2007·Application pending·0 cites
- 2158US2025221988A1Compounds and methods of treating cancersCULLGEN SHANGHAI INC·Filed 2023·Application pending·0 cites
- 2256US2025235543A1Modified proteins and protein degradersCULLGEN SHANGHAI INC·Filed 2022·Application pending·0 cites
- 2354US7692014B2Inhibitors of the HIV integrase enzymePFIZER·Filed 2005·Granted Apr 6, 2010·0 cites·4 claims
- 2454US2024197694A1Modified proteins and protein bindersCULLGEN SHANGHAI INC·Filed 2022·Application pending·0 cites
- 2554US2005203108A1Glucagon antagonists/inverse agonistsFiled 2004·Application pending·0 cites
- 2654US2023073777A1Cyclic-amp response element binding protein (cbp) and/or adenoviral e1a binding protein of 300 kda (p300) degradation compounds and methods of useCULLGEN SHANGHAI INC·Filed 2020·Application pending·0 cites
- 2753US2024050428A1Compounds and methods of treating cancersCULLGEN SHANGHAI INC·Filed 2021·Application pending·0 cites
- 2853US2024100170A1Cyclic-amp response element binding protein (cbp) and/or adenoviral e1a binding protein of 300 kda (p300) degradation compounds and methods of useCULLGEN SHANGHAI INC·Filed 2021·Application pending·0 cites
- 2951US12419865B2Compounds for the treatment of arenavirus infectionARISAN THERAPEUTICS INC·Filed 2019·Granted Sep 23, 2025·0 cites·19 claims
- 3046US2009170846A1Inhibitors of the hiv integrase enzymePFIZER·Filed 2006·Application pending·0 cites
- 3146US2023093099A1Compounds and methods of treating cancersCULLGEN SHANGHAI INC·Filed 2020·Application pending·0 cites
- 3244US12240857B2Adamantane derivatives for the treatment of filovirus infectionARISAN THERAPEUTICS INC·Filed 2018·Granted Mar 4, 2025·0 cites·20 claims
- 3340US2007232644A1Inhibitors of the Hiv Integrase EnzymePFIZER·Filed 2005·Application pending·0 cites
- 3439US2007099915A1Inhibitors of the hiv integrase enzymePFIZER·Filed 2006·Application pending·0 cites
- 3539US2010137283A1Inhibitors of the hiv integrase enzymePFIZER·Filed 2010·Application pending·0 cites
- 3637US11548893B2Enantiomerically pure adamantane carboxamides for the treatment of filovirus infectionARISAN THERAPEUTICS INC·Filed 2018·Granted Jan 10, 2023·0 cites·52 claims
- 3727US2012157471A1Benzimidazole derivativesNAIR SAJIV KRISHNAN·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Michael Bruno Plewe files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →